Rapport Therapeutics Inc. Common Stock (RAPP) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Rapport Therapeutics Inc....

    NASDAQ: RAPP · Real-Time Price · USD
    14.36
    -0.99 (-6.45%)
    At close: Sep 05, 2025, 3:59 PM

    Rapport Therapeutics Common Stock Income Statement

    Financials in USD. Fiscal year is undefined.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022
    Revenue
    		 n/a n/a n/a
    Cost of Revenue
    		 839K 112K 15K
    Gross Profit
    		 -839K -112K -15K
    Operating Income
    		 -83.06M -36.18M -10.37M
    Interest Income
    		 12.14M 2.53M n/a
    Pretax Income
    		 -78.31M -34.78M -10.65M
    Net Income
    		 -78.31M -34.79M -10.65M
    Selling & General & Admin
    		 22.12M 8.07M 1.24M
    Research & Development
    		 60.94M 28M 9.12M
    Other Expenses
    		 -839K n/a n/a
    Operating Expenses
    		 82.22M 36.07M 10.35M
    Interest Expense
    		 n/a n/a 285K
    Selling & Marketing Expenses
    		 n/a -112K n/a
    Cost & Expenses
    		 83.06M 36.18M 10.37M
    Income Tax Expense
    		 n/a 10K n/a
    Shares Outstanding (Basic)
    		 207.38M 180.79M 201.17M
    Shares Outstanding (Diluted)
    		 207.38M 180.79M 201.17M
    EPS (Basic)
    		 -0.38 -0.19 -0.05
    EPS (Diluted)
    		 -0.38 -0.19 -0.05
    EBITDA
    		 -77.47M -34.66M -10.35M
    EBIT
    		 -78.31M -34.78M -10.37M
    Depreciation & Amortization
    		 839K 112K 15K

    Add to Watchlist